Journal article
Case Report: Advanced grade 2 meningioma with PBRM1 inactivation with prolonged response to immunotherapy
Frontiers in oncology, Vol.15, 587752
10/22/2025
DOI: 10.3389/fonc.2025.1587752
PMCID: PMC12587182
PMID: 41199851
Abstract
Meningiomas are the most common primary tumor in the central nervous system, yet an effective systemic treatment remains a challenge. We present a grade 2 meningioma that resulted in a positive and prolonged response to pembrolizumab. Our case had polybromo-1 ( PBRM1 ) and BAP1 functional loss, tumor mutational burden of 4 Muts/Mb, stable microsatellite status, and a PD-L1 tumor proportion score of <1%. We add to the limited literature regarding PBRM1 mutations in meningiomas. We discuss our findings in relation to the ongoing investigation of immune checkpoint inhibitor therapy in treating higher-grade refractory meningiomas.
Details
- Title: Subtitle
- Case Report: Advanced grade 2 meningioma with PBRM1 inactivation with prolonged response to immunotherapy
- Creators
- Ellen ReuschKeng Hee PehRachael MorganHarry MomoDavid OrrenStephanie RockThomas PittmanJanna NeltnerJill KolesarJohn Villano
- Resource Type
- Journal article
- Publication Details
- Frontiers in oncology, Vol.15, 587752
- DOI
- 10.3389/fonc.2025.1587752
- PMID
- 41199851
- PMCID
- PMC12587182
- NLM abbreviation
- Front Oncol
- ISSN
- 2234-943X
- eISSN
- 2234-943X
- Publisher
- FRONTIERS MEDIA SA
- Grant note
- National Institutes of Health
The author(s) declare financial support was received for the research and/or publication of this article. The Research Communications Office of the University of Kentucky Markey Cancer Center (P30CA177558) supported the publication of the manuscript but did not contribute to the writing of the manuscript.
- Language
- English
- Date published
- 10/22/2025
- Academic Unit
- Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics; Obstetrics and Gynecology
- Record Identifier
- 9985019140102771
Metrics
22 Record Views